Biochemical and ultrastructural alterations accompany the anti-proliferative effect of butyrate on melanoma cells.
The effect of sodium butyrate on mouse and human melanoma cell lines was evaluated. Sodium butyrate (0.1-2mM) is shown to reduce the clonogenic potential of several melanoma cell lines. The antiproliferative effect of sodium butyrate is accompanied by a marked increase in the activity of the plasma-membrane bound enzyme gamma-glutamyl transpeptidase. Sodium butyrate treated cells acquire a well developed rough endoplasmic reticulum and accumulate fat droplets. The development of the endoplasmic reticulum is associated with a marked increase in the activity of the enzyme marker NADPH cytochrome c reductase. It is suggested that the phenotypic alterations induced by sodium butyrate may serve as markers for the action of this agent on melanoma cells and other tumours.
D000818:Animals; D002087:Butyrates / Q000627:therapeutic use*; D020148:Butyric Acid; D002460:Cell Line; D002999:Clone Cells / Q000187:drug effects; D004721:Endoplasmic Reticulum / Q000648:ultrastructure; D006801:Humans; D050356:Lipid Metabolism; D008545:Melanoma / Q000188:drug therapy* / Q000378:metabolism / Q000648:ultrastructure; D051379:Mice; D008854:Microscopy, Electron; D008938:Mitosis / Q000187:drug effects; D009251:NADPH-Ferrihemoprotein Reductase / Q000378:metabolism; D005723:gamma-Glutamyltransferase / Q000097:blood
D002087:Butyrates; D020148:Butyric Acid; D009251:NADPH-Ferrihemoprotein Reductase; D005723:gamma-Glutamyltransferase